Skip to main content

Advertisement

Log in

Clearance of amyloid-β by circulating lipoprotein receptors

  • Brief Communication
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Abstract

Low-density lipoprotein receptor–related protein-1 (LRP) on brain capillaries clears amyloid β-peptide (Aβ) from brain. Here, we show that soluble circulating LRP (sLRP) provides key endogenous peripheral 'sink' activity for Aβ in humans. Recombinant LRP cluster IV (LRP-IV) bound Aβ in plasma in mice and Alzheimer's disease–affected humans with compromised sLRP-mediated Aβ binding, and reduced Aβ-related pathology and dysfunction in a mouse model of Alzheimer disease, suggesting that LRP-IV can effectively replace native sLRP and clear Aβ.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: LRP-IV clears mouse endogenous brain Aβ, improves function and clears human brain Aβ in APP+/sw mice.
Figure 2: LRP-IV controls Aβ pathology in APP+/sw mice and sLRP and LRP-IV regulate peripheral Aβ in Alzheimer's disease.

Similar content being viewed by others

References

  1. Shibata, M. et al. J. Clin. Invest. 106, 1489–1499 (2000).

    Article  CAS  Google Scholar 

  2. Deane, R. et al. Neuron 43, 333–344 (2004).

    Article  CAS  Google Scholar 

  3. Tanzi, R.E., Moir, R.D. & Wagner, S.L. Neuron 43, 605–608 (2004).

    CAS  PubMed  Google Scholar 

  4. Bell, R.D. et al. J. Cereb. Blood Flow Metab. 27, 909–918 (2007).

    Article  CAS  Google Scholar 

  5. Tamaki, C. et al. Pharm. Res. 23, 1407–1416 (2006).

    Article  CAS  Google Scholar 

  6. von Arnim, C.A.F. et al. J. Biol. Chem. 280, 17777–17785 (2005).

    Article  CAS  Google Scholar 

  7. Quinn, K.A. et al. J. Biol. Chem. 272, 23946–23951 (1997).

    Article  CAS  Google Scholar 

  8. Westein, E., Denis, C.V., Bouma, B.N. & Lenting, P.J. J. Biol. Chem. 277, 2511–2516 (2002).

    Article  CAS  Google Scholar 

  9. Deane, R. et al. Nat. Med. 9, 907–913 (2003).

    Article  CAS  Google Scholar 

  10. Zerbinatti, C.V. & Bu, G.J. Rev. Neurosci. 16, 123–135 (2005).

    Article  CAS  Google Scholar 

  11. Jensen, G.A. et al. J. Mol. Biol. 362, 700–716 (2006).

    Article  CAS  Google Scholar 

  12. Kumar-Singh, S. et al. Am. J. Pathol. 167, 527–543 (2005).

    Article  CAS  Google Scholar 

  13. Hsiao, K. et al. Science 274, 99–102 (1996).

    Article  CAS  Google Scholar 

  14. Fryer, J.D. et al. J. Neurosci. 25, 2803–2810 (2005).

    Article  CAS  Google Scholar 

  15. Matsuoka, Y. et al. J. Neurosci. 23, 29–33 (2003).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by US National Institutes of Health (NIH) grants R37 AG023084 and R37 NS34467 to B.V.Z. and Washington University St. Louis Alzheimer's Disease Research Center grant P50 AG05681.

Author information

Authors and Affiliations

Authors

Contributions

A.S. conducted and performed in vivo studies in wild-type and APP+/sw (APPsw+/−) mice. R.D. conducted and performed pharmacokinetic and cerebral blood flow studies and work on the human study protocol. R.D.B. conducted and performed in vitro ligand binding assays and Aβ immunostaining studies. B.J. performed the oxidized sLRP assay and sLRP ELISA assay. K.H. performed in vivo studies in wild-type mice. R.P. purified recombinant LRP-IV. A.M. performed cholesterol and apoE assays. P.J.L. supervised R.P. and provided LRP-IV. Z.W. conducted and performed memory tests in mice. T.Z. performed approach and operant learning test in mice. D.P. performed active tPA and pro-MMP-9 assays. A.G. and K.M. performed LRP polymorphism studies. M.C. performed immunoprecipitation of oxidized proteins. Z.Z. performed Prussian blue staining. B.V.Z. designed the entire study, supervised all portions of the study and wrote the manuscript.

Corresponding author

Correspondence to Berislav V Zlokovic.

Ethics declarations

Competing interests

B.V.Z. is Scientific Founder and Program Director of Socratech LLC, a startup biotechnology company with a mission to develop therapeutics for Alzheimer's disease, stroke and other neurodegenerative disorders, and owns shares in the company. He does not receive direct financial compensation from Socratech LLC.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–7, Supplementary Table 1 and Methods (PDF 8244 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sagare, A., Deane, R., Bell, R. et al. Clearance of amyloid-β by circulating lipoprotein receptors. Nat Med 13, 1029–1031 (2007). https://doi.org/10.1038/nm1635

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1635

  • Springer Nature America, Inc.

This article is cited by

Navigation